CSL Limited (ASX: CSL) shares have plummeted to a new 5-year low, weighed down by restructuring announcements and weaker-than-expected profit forecasts, triggering concern among market participants. The critical A$200 level is now being closely watched as a potential support.
The stock hit a low of A$200.66, marking a year-to-date decline of 28%. This represents a significant downturn for the biotechnology giant, bringing the share price to levels not seen in over five years. The decline reflects market apprehension surrounding CSL’s strategic shift and its impact on future earnings.
The downward pressure on CSL shares intensified following the company’s August 19th announcement of a major restructuring plan. This included the decision to spin off its vaccine division and reduce its workforce by approximately 3,000 employees, representing about 15% of its staff outside the U.S. plasma unit.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The company cited challenges in vaccine profits, driven by what it described as “highly irrational” softness in the U.S. market, as well as slower growth in plasma collection operations. Despite reporting a 14% annual profit increase, the announcement triggered a sharp sell-off, with CSL’s share price dropping 15% in a single session, marking its worst day in history.
Further contributing to the negative sentiment was CSL’s annual profit forecast released in August 2024. The company projected a statutory net profit after tax between $3.2 billion and $3.3 billion for the 2025 financial year. While this figure represents an increase over the previous year’s $3.01 billion, it fell short of market expectations of $3.39 billion. This discrepancy led to a more than 3% decline in CSL’s share price at the time.
Technical analysis provides further insight into the stock’s bearish trend. As of September 8th, CSL’s 20-day exponential moving average stands at A$225.66, significantly above the current share price of A$209.25. The 50-day exponential moving average, at A$238.82, reinforces a bearish outlook.
The A$200 level may offer some psychological support for the stock. However, the combination of operational challenges, restructuring plans, and negative technical indicators suggests that markets remain cautious about CSL’s near-term prospects. The effectiveness of the restructuring and the company’s ability to meet future profit targets will be critical in determining the stock’s trajectory.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
